Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQTNASDAQ:BLTENASDAQ:DYNNASDAQ:IDYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$13.89-2.3%$13.92$7.42▼$17.75$1.66B1.762.26 million shs1.54 million shsBLTEBelite Bio$61.19-0.3%$60.69$43.70▼$86.53$1.95B-1.4448,097 shs39,882 shsDYNDyne Therapeutics$14.78+2.6%$10.77$6.36▼$47.45$1.68B1.171.67 million shs2.52 million shsIDYAIDEAYA Biosciences$22.63+4.2%$18.50$13.45▼$44.42$1.98B0.041.02 million shs1.11 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics-2.25%+4.67%+2.66%-8.38%+84.22%BLTEBelite Bio-0.34%-5.60%+0.26%-11.93%+24.78%DYNDyne Therapeutics+2.64%+11.38%+29.20%+19.58%-53.08%IDYAIDEAYA Biosciences+4.24%+4.57%+30.28%+21.67%-40.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARQTArcutis Biotherapeutics2.0572 of 5 stars3.41.00.00.02.71.70.6BLTEBelite Bio2.2596 of 5 stars3.53.00.00.02.10.80.6DYNDyne Therapeutics2.7716 of 5 stars4.51.00.00.01.53.30.0IDYAIDEAYA Biosciences3.9079 of 5 stars3.52.00.04.42.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.83Moderate Buy$18.8035.35% UpsideBLTEBelite Bio 3.00Buy$96.6757.98% UpsideDYNDyne Therapeutics 3.07Buy$45.54208.11% UpsideIDYAIDEAYA Biosciences 2.93Moderate Buy$54.27139.83% UpsideCurrent Analyst Ratings BreakdownLatest BLTE, IDYA, ARQT, and DYN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/2/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.00 ➝ $34.005/29/2025DYNDyne TherapeuticsEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$46.005/23/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.005/22/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.005/15/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight5/15/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.005/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/9/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.004/3/2025ARQTArcutis BiotherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/3/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 6/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$212.82M7.78N/AN/A$0.94 per share14.78BLTEBelite BioN/AN/AN/AN/A$3.28 per shareN/ADYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AIDYAIDEAYA Biosciences$7M283.14N/AN/A$12.10 per share1.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$262.14M-$1.04N/AN/AN/A-140.97%-119.11%-45.95%8/13/2025 (Estimated)BLTEBelite Bio-$31.63M-$1.36N/AN/AN/AN/A-31.94%-30.73%8/8/2025 (Estimated)DYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%8/11/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.59N/AN/AN/AN/A-26.74%-25.54%8/5/2025 (Estimated)Latest BLTE, IDYA, ARQT, and DYN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/6/2025Q1 2025ARQTArcutis Biotherapeutics-$0.21-$0.20+$0.01-$0.20$64.80 million$65.85 million5/6/2025Q1 2025IDYAIDEAYA Biosciences-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A3/17/2025Q4 2024BLTEBelite Bio-$0.30-$0.32-$0.02-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/ABLTEBelite BioN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.672.462.38BLTEBelite BioN/A30.7330.73DYNDyne TherapeuticsN/A17.0217.02IDYAIDEAYA BiosciencesN/A14.9722.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/ABLTEBelite Bio0.53%DYNDyne Therapeutics96.68%IDYAIDEAYA Biosciences98.29%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%BLTEBelite Bio13.29%DYNDyne Therapeutics14.14%IDYAIDEAYA Biosciences2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.20 million105.93 millionOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableDYNDyne Therapeutics100113.67 million80.63 millionOptionableIDYAIDEAYA Biosciences8087.58 million84.47 millionOptionableBLTE, IDYA, ARQT, and DYN HeadlinesRecent News About These CompaniesHere's Why Steve Cohen's Point72 Recently Shelled Out Over $100M for Two Biopharma StocksJune 10 at 1:32 PM | msn.comCantor Fitzgerald Forecasts IDYA FY2026 EarningsJune 10 at 8:57 AM | marketbeat.comIDEAYA Biosciences to Participate in Upcoming June 2025 Investor Relations EventsJune 2, 2025 | prnewswire.comMillennium Management LLC Cuts Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)June 1, 2025 | marketbeat.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 30, 2025 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Position Increased by Voloridge Investment Management LLCMay 27, 2025 | marketbeat.comSquarepoint Ops LLC Buys 33,088 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 27, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Sold by Two Sigma Investments LPMay 26, 2025 | marketbeat.comNeo Ivy Capital Management Makes New Investment in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 25, 2025 | marketbeat.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 24, 2025 | marketbeat.comJPMorgan Chase & Co. Issues Positive Forecast for IDEAYA Biosciences (NASDAQ:IDYA) Stock PriceMay 24, 2025 | marketbeat.comTwinbeech Capital LP Sells 71,664 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 24, 2025 | marketbeat.comBank of America Corp DE Acquires 41,390 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 22, 2025 | marketbeat.comJane Street Group LLC Reduces Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 22, 2025 | marketbeat.comTema Etfs LLC Purchases New Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 21, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Lowers Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 20, 2025 | marketbeat.comPolar Capital Holdings Plc Sells 589,500 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 19, 2025 | marketbeat.comDeutsche Bank AG Grows Position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 19, 2025 | marketbeat.comJanuary 2026 Options Now Available For IDEAYA BiosciencesMay 17, 2025 | nasdaq.comMPM Bioimpact LLC Buys Shares of 414,035 IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 16, 2025 | marketbeat.comJanus Henderson Group PLC Acquires 695,263 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)May 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBLTE, IDYA, ARQT, and DYN Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$13.89 -0.32 (-2.25%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$14.42 +0.54 (+3.85%) As of 07:43 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Belite Bio NASDAQ:BLTE$61.19 -0.21 (-0.34%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$61.26 +0.08 (+0.12%) As of 06/10/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Dyne Therapeutics NASDAQ:DYN$14.78 +0.38 (+2.64%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$14.71 -0.07 (-0.47%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.IDEAYA Biosciences NASDAQ:IDYA$22.63 +0.92 (+4.24%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$22.86 +0.23 (+0.99%) As of 04:03 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock Hits All-Time Highs: Smart Buy or FOMO Trap? These 3 Stocks Could Be Back in Play Before You Know It Casey’s Surges on Strong Q4, More Gains Likely Ahead Qualcomm: What Monday’s Jump Tells Us About the Stock's Prospects D-Wave Is Soaring—But Is ETF Diversification the Better Strategy? Government Mandate Sends eVTOL Stocks Flying AppLovin Dips on S&P 500 Snub, Morgan Stanley Lifts Target Anyway Meta Pulls Ahead of the Mag 7: Analysts Predict a Breakout Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
